Pfizer Inc. (PFE) announced on Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody targeting growth differentiation factor-15 (GDF-15), successfully met its primary endpoint. The study revealed a statistically significant change in body weight from baseline compared to placebo among participants suffering from cancer cachexia with elevated GDF-15 levels.The company highlighted that ponsegromab not only led to an increase in body weight but also resulted in enhancements in muscle mass, quality of life, and physical function.The Phase 2 study enrolled 187 participants diagnosed with non-small cell lung cancer, pancreatic cancer, or colorectal cancer. Findings indicated that ponsegromab produced significant and consistent body weight increases after 12 weeks across all dosage levels: 2.02% (95% confidence interval (CI), -0.97 to 5.01%) for the 100 mg group, 3.48% (95% CI, 0.54 to 6.42%) for the 200 mg group, and 5.61% (95% CI, 2.56 to 8.67%) for the 400 mg group, when compared to the placebo group.Moreover, the company observed improvements in several facets of the cachexia phenotype in the 400 mg dosage group, including measures of appetite, cachexia symptoms, physical activity, and skeletal muscle index. No clinically significant adverse trends were associated with ponsegromab treatment. Treatment-related adverse events were reported in 8.9% of patients receiving placebo and 7.7% of patients treated with ponsegromab.The material has been provided by InstaForex Company – www.instaforex.com
- Czech Retail Sales Growth Accelerates in August, Reaching 5.30% - October 8, 2024
- Czech Unemployment Rate Sees Slight Uptick in September - October 8, 2024
- France Sees Rise in Imports: August Figures Show a Notable Increase - October 8, 2024
